Aven Lee

Dr. Aven Lee


Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2007 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
SSSusan M. Sullivan
Susan M. Sullivan
ALAven Lee
Aven Lee
TBTracey Bjorkman
Tracey Bjorkman
SMStephanie M. Miller
Stephanie M. Miller
RSRobert K. P. Sullivan
Robert K. P. Sullivan
DPDavid V. Pow
David V. Pow
Glial fibrillary acidic protein (GFAP) is an enigmatic protein; it currently has no unambiguously defined role. It is expressed in the cytoskeleton of astrocytes in the mammalian brain. We have used co-immunoprecipitation to identify in vivo binding partners for GFAP in the rat and pig brain. We demonstrate interactions between GFAP, the glutamate transporter GLAST, the PDZ-binding protein NHERF1, and ezrin. These interactions are physiologically relevant; we demonstrate in vitro that transport of d-aspartate (a glutamate analogue) is significantly increased in the presence of GFAP and NHERF1. Moreover, we demonstrate in vivo that expression of GFAP is essential in retaining GLAST in the plasma membranes of astrocytes after an hypoxic insult. These data indicate that the cytoskeleton of the astrocyte plays an important role in protecting the brain against glutamate-mediated excitotoxicity.

1 December 2010 in The International Journal of Biochemistry & Cell Biology
Verified
Journal Article
Closed access
ALAven Lee
Aven Lee
DPDavid V. Pow
David V. Pow

17 October 2006 in Glia
Verified
Journal Article
Closed access
PDF file
ALAven Lee
Aven Lee
ARAndrew Rayfield
Andrew Rayfield
Deanne H HryciwDeanne H Hryciw
Deanne H Hryciw
TMTheingi Aung Ma
Theingi Aung Ma
DWDongsheng Wang
Dongsheng Wang
PPPhilip Poronnik
Philip Poronnik

1 May 2010 in Journal of Chemical Neuroanatomy
Verified
Journal Article
Closed access
ALAven Lee
Aven Lee
BLBarbara E. Lingwood
Barbara E. Lingwood
TBTracey Bjorkman
Tracey Bjorkman
SMStephanie M. Miller
Stephanie M. Miller
PPPhilip Poronnik
Philip Poronnik
DPDavid V. Pow
David V. Pow

Verified
Journal Article
Open access
PDF file
ALAven Lee
Aven Lee
RHRobert Henderson
Robert Henderson
JAJames Aylward
James Aylward
PMPamela Ann McCombe
Pamela Ann McCombe
Many pathogenetic mechanisms have been proposed for amyotrophic lateral sclerosis (ALS). Recently, there have been emerging suggestions of a possible role for the gut microbiota. Gut microbiota have a range of functions and could influence ALS by several mechanisms. Here, we review the possible role of gut-derived neurotoxins/excitotoxins. We review the evidence of gut symptoms and gut dysbiosis in ALS. We then examine a possible role for gut-derived toxins by reviewing the evidence that these molecules are toxic to the central nervous system, evidence of their association with ALS, the existence of biochemical pathways by which these molecules could be produced by the gut microbiota and existence of mechanisms of transport from the gut to the blood and brain. We then present evidence that there are increased levels of these toxins in the blood of some ALS patients. We review the effects of therapies that attempt to alter the gut microbiota or ameliorate the biochemical effects of gut toxins. It is possible that gut dysbiosis contributes to elevated levels of toxins and that these could potentially contribute to ALS pathogenesis, but more work is required.

1 February 2011 in Cellular Physiology and Biochemistry
Verified
Journal Article
Closed access
PDF file
Slattery CraigSlattery Craig
Slattery Craig
KJKayte A. Jenkin
Kayte A. Jenkin
ALAven Lee
Aven Lee
ASAnna C. Simcocks
Anna C. Simcocks
AMAndrew McAinch
Andrew McAinch
Deanne H HryciwDeanne H Hryciw
Deanne H Hryciw
The scavenger receptor megalin binds to albumin in the microvilli of the renal proximal tubule, and transports the ligand to the intravillar cleft for processing by endocytosis. Albumin endocytosis in the proximal tubule is regulated by protein complexes containing a number of transmembrane and accessory proteins including PDZ scaffolds such as NHERF1 and NHERF2. PDZ scaffold proteins bind to class I PDZ binding motifs (S/T-X-Φ) in the extreme C-terminus of targets. Megalin contains a functional PDZ binding motif (SDV) in its distal terminus, however a potential interaction with the NHERF proteins has not been investigated. As megalin associates with NHE3 in the microvilli and NHE3 is tethered to the intravillar cleft via its interaction with NHERF1, we investigated if there is a direct interaction between megalin and NHERF1 in renal proximal tubule cells. Using confocal microscopy we determined that megalin and NHERF1 co-localise in the apical region in proximal tubule cells. Immunoprecipitation experiments performed using rat kidney lysate indicated that megalin bound NHERF1 in vivo. Using fusion proteins and peptides, we determined that PDZ2 of NHERF1 bound to megalin and that this interaction was via the C-terminus of megalin directly and in the absence of any accessory protein. We next investigated which domain in megalin was regulating this interaction. Using GST fusion proteins we determined that the loss of the most distal C-terminus of megalin containing the PDZ binding motif (SDV) did not alter its ability to bind to NHERF1. Significantly, we then identified an internal NHERF binding domain in the C-terminus of megalin. Using peptide studies we were able to demonstrate that NHERF1 bound to an internal PDZ binding motif in megalin and that a loss of a single threonine residue abolished the interaction between megalin and NHERF1. Finally, in proximal tubule cells, silencing NHERF1 increased megalin expression. Therefore, we have identified a novel protein interaction in proximal tubule cells and specifically identified a new internal PDZ binding motif in the C-terminus of megalin.